CHMP recommends suspension of marketing approval for Ionsys
Janssen-Cilag recalled Ionsys in the European Union (EU) in September 2008, as a precautionary measure following identification of corrosion in a component of the system in one lot
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.